Efficacy And Safety Of Indobufen Plus Clopidogrel For Postoperative PCI In Patients With ACS Who Are At High Risk For Gastrointestinal Bleeding

Objective: To evaluate the efficacy and safety of indobufen plus clopidogrel hydrogen sulfate antiplatelet therapy before and after percutaneous coronary intervention in patients with acute coronary syndrome who are at high risk of gastrointestinal bleeding.Methods: This study was a prospective case-control study involving 76 patients with a clear diagnosis of ACS who had a high risk of gastrointestinal bleeding and who required PCI.They were randomized to the experimental group of indobufen plus clopidogrel hydrogen sulfate.In 38 cases,the control group received aspirin combined with clopidogrel hydrogen sulfate in 38 cases.The platelet count(PLT),the adenosine diphosphate and arachidonic acid-induced platelet aggregation rate(MAR)and the aggregation inhibition rate were observed.IPMI)and TIMI blood flow before and after PCI.The treatment outcomes of 12-month patients,major cardiovascular adverse events(MACE),drug tolerance,and bleeding were counted.Results: There was no significant difference in the baseline data between the two groups(P>0.05).There was no significant difference in TIMI blood flow between the experimental group and the control group before and after PCI(P>0.05).The experimental group and the control group were administered before and after 7 days.The maximum platelet aggregation rate(MAR)and aggregation inhibition rate(IPA)induced by adenosine diphosphate and arachidonic acid in platelet count(PLT)after 1 month and 3 months of treatment were not statistically significant(P>0.05).There was no significant difference in the treatment effect between the two groups(P>0.05).There was no significant difference in the incidence of MACE between the two groups(P>0.05).The indobufen resistance was significantly stronger than that of aspirin.(P<0.05).According to the TIMI bleeding grading,there was no significant difference between the experimental group and the control group(P>0.05).The gastrointestinal bleeding event in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion: Indobufen was not statistically different from aspirin in terms of platelet count,platelet aggregation rate,and angina pectoris treatment.Patients with ACS complicated with high gastrointestinal bleeding were effective after PCI,and the risk of gastrointestinal bleeding was small.